Lexrite is a research-driven enterprise engaged in developing the next generation of molecular tools for finding and treating cancer. Lexrite's scientists are integrating chemistry with biology to discover new targeted therapies. Using expertise in molecular biology and organic chemistry, the firms have engineered protein molecules that bind permanently to their targets (Irreversible Antibodies), increasing the potency and efficacy of antibodies. Lexrite Labs is strategically positioned to enhance a variety of monoclonal antibody therapeutics and drug candidates worldwide.
